Celastrol: A new potential therapeutic option in pulmonary hypertension associated with bronchopulmonary dysplasia

C.-M. Pilard , G. Cardouat , I. Gauthereau , P. Robillard , F. Sauvestre , F. Pelluard , S. Berenguer , L. Sentilhes , F. Coatleven , L. Renesme , E. Dumas-De-La-Roque , R. Marthan , P. Berger , V. Freund-Michel , C. Guibert
{"title":"Celastrol: A new potential therapeutic option in pulmonary hypertension associated with bronchopulmonary dysplasia","authors":"C.-M. Pilard ,&nbsp;G. Cardouat ,&nbsp;I. Gauthereau ,&nbsp;P. Robillard ,&nbsp;F. Sauvestre ,&nbsp;F. Pelluard ,&nbsp;S. Berenguer ,&nbsp;L. Sentilhes ,&nbsp;F. Coatleven ,&nbsp;L. Renesme ,&nbsp;E. Dumas-De-La-Roque ,&nbsp;R. Marthan ,&nbsp;P. Berger ,&nbsp;V. Freund-Michel ,&nbsp;C. Guibert","doi":"10.1016/j.acvdsp.2023.07.040","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p><span>Bronchopulmonary dysplasia is a common pathology of premature newborns caused by oxygen and </span>mechanical ventilation<span>, resulting in hypoalveolarization and impaired angiogenesis<span>. It can be complicated by pulmonary hypertension (PH-BPD) with excess mortality. Celastrol has anti-inflammatory and antioxidant properties.</span></span></p></div><div><h3>Objective</h3><p>We addressed potential therapeutic interest of celastrol in PH-BPD.</p></div><div><h3>Methods</h3><p>Different concentrations of celastrol (0,1–0,5–1<!--> <!-->mg/kg/d) were tested in a murine model of hyperoxic PH-BPD (14 days with 90% O<sub>2</sub><span>–Hx). We evaluated hemodynamic<span> parameters with echocardiography, lung remodeling with histological methods and pulmonary arterial (PA) reactivity with myograph. Cytoplasmic calcium (Ca</span></span><sub>2</sub><span><span>+i) response to endothelin-1 (ET-1) was evaluated in human fetal PA smooth muscle cells (fPASMC) with </span>spectrophotometry in normoxic (21% O</span><sub>2</sub>) and Hx conditions (48<!--> <!-->h with 60% O<sub>2</sub><span>). Inflammation and oxidant stress were also addressed.</span></p></div><div><h3>Results/Expected results</h3><p>Celastrol reduces mortality at doses of 1 and 0,5<!--> <!-->mg/kg/d compared to Hx control. At 1<!--> <span><span><span>mg/kg/d, it normalizes PA acceleration time and reduces vascular hyperreactivity to ET-1 inversely to phenylephrine and 5-HT, with no effect on the altered response to </span>acetylcholine induced by Hx. At all doses, it decreases right </span>heart hypertrophy<span><span> and vascular remodeling<span> but has no effect on media cells proliferation observed in Hx condition. It has also no impact on </span></span>alveolarization and vascular density. Although celastrol (0.1 and 0.3</span></span> <!-->μM) decreases the increased Ca<sub>2</sub><span>+i response to ET-1 in Hx in fPASMC, expression of ET-1 receptors was unchanged. In fPASMC, celastrol 0.3</span> <span>μM decreases the increased concentration of IL6 observed in Hx but has no effect on IL8 and MIF. In both models, Hx-induced oxidant stress remains mild with absence of protein carbonylation<span> and lipid peroxidation and celastrol at 1</span></span> <span>mg/kg/d increases heme oxygenase 1 expression.</span></p></div><div><h3>Conclusion/Perspectives</h3><p>Celastrol has a preventive dose-dependent effect on major hallmarks of PH induced by Hx and could be considered as a new potential therapeutic option for PH-BPD.</p></div>","PeriodicalId":8140,"journal":{"name":"Archives of Cardiovascular Diseases Supplements","volume":null,"pages":null},"PeriodicalIF":18.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Cardiovascular Diseases Supplements","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1878648023002616","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Bronchopulmonary dysplasia is a common pathology of premature newborns caused by oxygen and mechanical ventilation, resulting in hypoalveolarization and impaired angiogenesis. It can be complicated by pulmonary hypertension (PH-BPD) with excess mortality. Celastrol has anti-inflammatory and antioxidant properties.

Objective

We addressed potential therapeutic interest of celastrol in PH-BPD.

Methods

Different concentrations of celastrol (0,1–0,5–1 mg/kg/d) were tested in a murine model of hyperoxic PH-BPD (14 days with 90% O2–Hx). We evaluated hemodynamic parameters with echocardiography, lung remodeling with histological methods and pulmonary arterial (PA) reactivity with myograph. Cytoplasmic calcium (Ca2+i) response to endothelin-1 (ET-1) was evaluated in human fetal PA smooth muscle cells (fPASMC) with spectrophotometry in normoxic (21% O2) and Hx conditions (48 h with 60% O2). Inflammation and oxidant stress were also addressed.

Results/Expected results

Celastrol reduces mortality at doses of 1 and 0,5 mg/kg/d compared to Hx control. At 1 mg/kg/d, it normalizes PA acceleration time and reduces vascular hyperreactivity to ET-1 inversely to phenylephrine and 5-HT, with no effect on the altered response to acetylcholine induced by Hx. At all doses, it decreases right heart hypertrophy and vascular remodeling but has no effect on media cells proliferation observed in Hx condition. It has also no impact on alveolarization and vascular density. Although celastrol (0.1 and 0.3 μM) decreases the increased Ca2+i response to ET-1 in Hx in fPASMC, expression of ET-1 receptors was unchanged. In fPASMC, celastrol 0.3 μM decreases the increased concentration of IL6 observed in Hx but has no effect on IL8 and MIF. In both models, Hx-induced oxidant stress remains mild with absence of protein carbonylation and lipid peroxidation and celastrol at 1 mg/kg/d increases heme oxygenase 1 expression.

Conclusion/Perspectives

Celastrol has a preventive dose-dependent effect on major hallmarks of PH induced by Hx and could be considered as a new potential therapeutic option for PH-BPD.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
雷公藤红素:支气管肺发育不良伴肺动脉高压的一种新的潜在治疗选择
支气管肺发育不良是早产新生儿由氧气和机械通气引起的常见病理,导致肺泡发育降低和血管生成受损。它可并发肺动脉高压(PH-BPD),死亡率高。Celastrol具有抗炎和抗氧化的特性。目的探讨雷公藤红素在PH-BPD中的潜在治疗价值。方法采用高氧PH-BPD小鼠模型(90% O2-Hx 14 d),测定不同浓度的celastrol(0、1-0、5-1 mg/kg/d)。我们用超声心动图评估血流动力学参数,用组织学方法评估肺重塑,用肌图评估肺动脉反应性。用分光光度法测定了人胎儿PA平滑肌细胞(fPASMC)在常氧(21% O2)和高氧(60% O2)条件下(48 h)细胞质钙(Ca2+i)对内皮素-1 (ET-1)的反应。炎症和氧化应激也得到了解决。结果/预期结果与Hx对照相比,1和0.5 mg/kg/d剂量的雷公藤酚可降低死亡率。在1 mg/kg/d时,它使PA加速时间正常化,并降低血管对ET-1的高反应性,而与苯肾上腺素和5-HT相反,对Hx诱导的乙酰胆碱反应的改变没有影响。在所有剂量下,它都能减少右心肥厚和血管重构,但对Hx条件下观察到的介质细胞增殖没有影响。它对肺泡化和血管密度也没有影响。虽然雷公藤红素(0.1 μM和0.3 μM)降低了fPASMC中Hx中增加的ET-1对Ca2+i的响应,但ET-1受体的表达不变。在fPASMC中,celastrol 0.3 μM降低了Hx中IL6浓度的升高,但对IL8和MIF没有影响。在这两种模型中,hx诱导的氧化应激都是轻度的,没有蛋白质羰基化和脂质过氧化,1 mg/kg/d的celastrol增加了血红素加氧酶1的表达。结论/观点celastrol对Hx诱导的PH主要标志物具有剂量依赖性的预防作用,可被认为是PH- bpd的一种新的潜在治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Archives of Cardiovascular Diseases Supplements
Archives of Cardiovascular Diseases Supplements CARDIAC & CARDIOVASCULAR SYSTEMS-
自引率
0.00%
发文量
508
期刊介绍: Archives of Cardiovascular Diseases Supplements is the official journal of the French Society of Cardiology. The journal publishes original peer-reviewed clinical and research articles, epidemiological studies, new methodological clinical approaches, review articles, editorials, and Images in cardiovascular medicine. The topics covered include coronary artery and valve diseases, interventional and pediatric cardiology, cardiovascular surgery, cardiomyopathy and heart failure, arrhythmias and stimulation, cardiovascular imaging, vascular medicine and hypertension, epidemiology and risk factors, and large multicenter studies. Additionally, Archives of Cardiovascular Diseases also publishes abstracts of papers presented at the annual sessions of the Journées Européennes de la Société Française de Cardiologie and the guidelines edited by the French Society of Cardiology.
期刊最新文献
Editorial Contents How to Report postoperative pediatric cardiac surgery? Review and analysis of the literature Surgical or transcatheter pulmonary valve replacement, how to choose ? No coronary artery in the aorta: Severe congenital malformation under-diagnosed
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1